Control of systemic and local inflammation with transforming growth factor beta containing formulas.
Enteral nutrition therapy with liquid diet has been shown to be effective in achieving clinical remission in intestinal Crohn's disease. The mechanism of action of this therapy, however, is still poorly understood. As part of our assessment of the action of 3 related polymeric enteral therapies, we have used a variety of techniques to document the histological and cytokine responses, in the mucosa and, systemically, to these treatments. The feeds studied (AL110, Modulen IBD and ACD004 [Nestle, Vevey, Switzerland]) all have casein as the protein source, are lactose free and are rich in transforming growth factor beta (TGF-beta). They have all been shown to induce clinical remission associated with mucosal healing. In the case of Modulen IBD, as well as mucosal macroscopic and histological healing there was a fall in mucosal proinflammatory cytokines: interleukin-1 mRNA in colonic and ileal, interleukin-8 mRNA in the colon and interferon gamma mRNA in the ileum, but a rise in the regulatory cytokine TGF-beta mRNA in the ileum. These results indicate that these formulas are influencing the disease process itself, and thus suggest that the clinical remission achieved is a result of a reduction in inflammation, rather than a consequence of some other nutrition effect.
Department of Pediatric Gastroenterology, Chelsea and Westminster Hospital, London, United Kingdom. j.fell@imperial.ac.uk
John M E
JM
Fell
D003424:Crohn Disease / Q000628:therapy; D016207:Cytokines / Q000096:biosynthesis / Q000187:drug effects; D004750:Enteral Nutrition; D006801:Humans; D007249:Inflammation / Q000628:therapy; D015212:Inflammatory Bowel Diseases / Q000628:therapy*; D007413:Intestinal Mucosa / Q000276:immunology / Q000473:pathology; D012074:Remission Induction; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*
D016207:Cytokines; D016212:Transforming Growth Factor beta